Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the ...
Morning Overview on MSN
RNA-guided CRISPR tool turns genes on with dose control
Researchers have built a series of CRISPR-based platforms that can switch endogenous genes on and, just as critically, dial ...
On remand from the Federal Circuit, the Patent Trial and Appeal Board on Thursday reaffirmed its decision that The Broad ...
A US patent board last week backed the Broad Institute’s claim to CRISPR use in human and animal cells, not the Nobel winners ...
Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the U.S. Patent and Trademark Office ...
The powerful gene-editing technique CRISPR–Cas9 might offer a way to make safer, more effective cancer-fighting immune cells ...
Scientists from the University of Sheffield, the MRC Laboratory of Medical Sciences (LMS) and Imperial College London have helped solve a decade-long ...
Editas Medicine announces USPTO reaffirms its prior decision in favour of the Broad Institute in CRISPR/Cas9 interference: Cambridge, Massachusetts Monday, March 30, 2026, 15:00 H ...
Scientists at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Milan, have found that gene editing using CRISPR-Cas9 in combination with AAV6 vectors can trigger inflammatory and ...
CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the top gene therapy stocks to buy according to hedge funds. On February 17, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results